Polymeric nanoparticulate drug delivery through the blood brain barrier

Celeste Roney, Padmakar Kulkarni, Veera Arora, Michael Bennett, Peter Antich, Frederick Bonte, Aimei Wu, N. N. Mallikarjuna, Sanjeev Manohar, Malladi Sairam, Tejraj M. Aminabhavi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is the most common cause of dementia among the elderly, affecting 5% of Americans over age 65, and 20% over age 80. An excess of senile plaques (β-amyloid protein) and neurofibrillary tangles (tau protein), ventricular enlargement, and cortical atrophy characterizes it. Unfortunately, targeted drug delivery to the Central Nervous System (CNS), for the therapeutic advancement of neurodegenerative disorders such as Alzheimer's, is complicated by restrictive mechanisms imposed at the blood brain barrier (BBB). Opsonization by plasma proteins in the systemic circulation is an additional impediment to cerebral drug delivery. Here, we attempt to show that biodegradable polymeric nanoparticles (NPs) with appropriate surface modifications can deliver drugs of interest beyond the BBB for diagnostic and therapeutic applications, thus allowing the study of neurological disorders. Particularly, the radiolabelled Cu2+ or Fe3+ metal chelator Clioquinol (CQ), which has a high affinity for amyloid plaques with a radio-isotope 125I, and encapsulated 125I-CQ within small, spherical, lipophilic drug carriers are capable of crossing the BBB. In this feature article, the biodistribution patterns of such nanoparticle drug carriers in wild type Swiss Webster mice are compared with free 125I-CQ. The physicochemical properties of the NPs at different surfactant concentrations, stabilizers, and amyloid-affinity agents could influence the transport mechanism.

Original languageEnglish (US)
Pages (from-to)311-321
Number of pages11
JournalPolymer News
Volume30
Issue number10
DOIs
StatePublished - Oct 2005

Fingerprint

Clioquinol
Drug delivery
Drug Carriers
Nanoparticles
Amyloid
Proteins
Amyloidogenic Proteins
Stabilizers (agents)
tau Proteins
Neurology
Chelating Agents
Surface-Active Agents
Isotopes
Surface treatment
Blood Proteins
Surface active agents
Metals
Plasmas
Pharmaceutical Preparations
Blood-Brain Barrier

Keywords

  • AD metallobiology
  • Alzheimer's disease
  • Amyloid-beta protein
  • Blood brain barrier
  • Clioquinol

ASJC Scopus subject areas

  • Polymers and Plastics
  • Chemical Engineering (miscellaneous)

Cite this

Roney, C., Kulkarni, P., Arora, V., Bennett, M., Antich, P., Bonte, F., ... Aminabhavi, T. M. (2005). Polymeric nanoparticulate drug delivery through the blood brain barrier. Polymer News, 30(10), 311-321. https://doi.org/10.1080/00323910500290374

Polymeric nanoparticulate drug delivery through the blood brain barrier. / Roney, Celeste; Kulkarni, Padmakar; Arora, Veera; Bennett, Michael; Antich, Peter; Bonte, Frederick; Wu, Aimei; Mallikarjuna, N. N.; Manohar, Sanjeev; Sairam, Malladi; Aminabhavi, Tejraj M.

In: Polymer News, Vol. 30, No. 10, 10.2005, p. 311-321.

Research output: Contribution to journalArticle

Roney, C, Kulkarni, P, Arora, V, Bennett, M, Antich, P, Bonte, F, Wu, A, Mallikarjuna, NN, Manohar, S, Sairam, M & Aminabhavi, TM 2005, 'Polymeric nanoparticulate drug delivery through the blood brain barrier', Polymer News, vol. 30, no. 10, pp. 311-321. https://doi.org/10.1080/00323910500290374
Roney C, Kulkarni P, Arora V, Bennett M, Antich P, Bonte F et al. Polymeric nanoparticulate drug delivery through the blood brain barrier. Polymer News. 2005 Oct;30(10):311-321. https://doi.org/10.1080/00323910500290374
Roney, Celeste ; Kulkarni, Padmakar ; Arora, Veera ; Bennett, Michael ; Antich, Peter ; Bonte, Frederick ; Wu, Aimei ; Mallikarjuna, N. N. ; Manohar, Sanjeev ; Sairam, Malladi ; Aminabhavi, Tejraj M. / Polymeric nanoparticulate drug delivery through the blood brain barrier. In: Polymer News. 2005 ; Vol. 30, No. 10. pp. 311-321.
@article{a015dad79e1d41638d60e04a6b27c87e,
title = "Polymeric nanoparticulate drug delivery through the blood brain barrier",
abstract = "Alzheimer's disease (AD) is the most common cause of dementia among the elderly, affecting 5{\%} of Americans over age 65, and 20{\%} over age 80. An excess of senile plaques (β-amyloid protein) and neurofibrillary tangles (tau protein), ventricular enlargement, and cortical atrophy characterizes it. Unfortunately, targeted drug delivery to the Central Nervous System (CNS), for the therapeutic advancement of neurodegenerative disorders such as Alzheimer's, is complicated by restrictive mechanisms imposed at the blood brain barrier (BBB). Opsonization by plasma proteins in the systemic circulation is an additional impediment to cerebral drug delivery. Here, we attempt to show that biodegradable polymeric nanoparticles (NPs) with appropriate surface modifications can deliver drugs of interest beyond the BBB for diagnostic and therapeutic applications, thus allowing the study of neurological disorders. Particularly, the radiolabelled Cu2+ or Fe3+ metal chelator Clioquinol (CQ), which has a high affinity for amyloid plaques with a radio-isotope 125I, and encapsulated 125I-CQ within small, spherical, lipophilic drug carriers are capable of crossing the BBB. In this feature article, the biodistribution patterns of such nanoparticle drug carriers in wild type Swiss Webster mice are compared with free 125I-CQ. The physicochemical properties of the NPs at different surfactant concentrations, stabilizers, and amyloid-affinity agents could influence the transport mechanism.",
keywords = "AD metallobiology, Alzheimer's disease, Amyloid-beta protein, Blood brain barrier, Clioquinol",
author = "Celeste Roney and Padmakar Kulkarni and Veera Arora and Michael Bennett and Peter Antich and Frederick Bonte and Aimei Wu and Mallikarjuna, {N. N.} and Sanjeev Manohar and Malladi Sairam and Aminabhavi, {Tejraj M.}",
year = "2005",
month = "10",
doi = "10.1080/00323910500290374",
language = "English (US)",
volume = "30",
pages = "311--321",
journal = "Polymer News",
issn = "0032-3918",
publisher = "Taylor and Francis Ltd.",
number = "10",

}

TY - JOUR

T1 - Polymeric nanoparticulate drug delivery through the blood brain barrier

AU - Roney, Celeste

AU - Kulkarni, Padmakar

AU - Arora, Veera

AU - Bennett, Michael

AU - Antich, Peter

AU - Bonte, Frederick

AU - Wu, Aimei

AU - Mallikarjuna, N. N.

AU - Manohar, Sanjeev

AU - Sairam, Malladi

AU - Aminabhavi, Tejraj M.

PY - 2005/10

Y1 - 2005/10

N2 - Alzheimer's disease (AD) is the most common cause of dementia among the elderly, affecting 5% of Americans over age 65, and 20% over age 80. An excess of senile plaques (β-amyloid protein) and neurofibrillary tangles (tau protein), ventricular enlargement, and cortical atrophy characterizes it. Unfortunately, targeted drug delivery to the Central Nervous System (CNS), for the therapeutic advancement of neurodegenerative disorders such as Alzheimer's, is complicated by restrictive mechanisms imposed at the blood brain barrier (BBB). Opsonization by plasma proteins in the systemic circulation is an additional impediment to cerebral drug delivery. Here, we attempt to show that biodegradable polymeric nanoparticles (NPs) with appropriate surface modifications can deliver drugs of interest beyond the BBB for diagnostic and therapeutic applications, thus allowing the study of neurological disorders. Particularly, the radiolabelled Cu2+ or Fe3+ metal chelator Clioquinol (CQ), which has a high affinity for amyloid plaques with a radio-isotope 125I, and encapsulated 125I-CQ within small, spherical, lipophilic drug carriers are capable of crossing the BBB. In this feature article, the biodistribution patterns of such nanoparticle drug carriers in wild type Swiss Webster mice are compared with free 125I-CQ. The physicochemical properties of the NPs at different surfactant concentrations, stabilizers, and amyloid-affinity agents could influence the transport mechanism.

AB - Alzheimer's disease (AD) is the most common cause of dementia among the elderly, affecting 5% of Americans over age 65, and 20% over age 80. An excess of senile plaques (β-amyloid protein) and neurofibrillary tangles (tau protein), ventricular enlargement, and cortical atrophy characterizes it. Unfortunately, targeted drug delivery to the Central Nervous System (CNS), for the therapeutic advancement of neurodegenerative disorders such as Alzheimer's, is complicated by restrictive mechanisms imposed at the blood brain barrier (BBB). Opsonization by plasma proteins in the systemic circulation is an additional impediment to cerebral drug delivery. Here, we attempt to show that biodegradable polymeric nanoparticles (NPs) with appropriate surface modifications can deliver drugs of interest beyond the BBB for diagnostic and therapeutic applications, thus allowing the study of neurological disorders. Particularly, the radiolabelled Cu2+ or Fe3+ metal chelator Clioquinol (CQ), which has a high affinity for amyloid plaques with a radio-isotope 125I, and encapsulated 125I-CQ within small, spherical, lipophilic drug carriers are capable of crossing the BBB. In this feature article, the biodistribution patterns of such nanoparticle drug carriers in wild type Swiss Webster mice are compared with free 125I-CQ. The physicochemical properties of the NPs at different surfactant concentrations, stabilizers, and amyloid-affinity agents could influence the transport mechanism.

KW - AD metallobiology

KW - Alzheimer's disease

KW - Amyloid-beta protein

KW - Blood brain barrier

KW - Clioquinol

UR - http://www.scopus.com/inward/record.url?scp=32044466070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32044466070&partnerID=8YFLogxK

U2 - 10.1080/00323910500290374

DO - 10.1080/00323910500290374

M3 - Article

AN - SCOPUS:32044466070

VL - 30

SP - 311

EP - 321

JO - Polymer News

JF - Polymer News

SN - 0032-3918

IS - 10

ER -